Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-17 08:33 4746

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2023-04-17 08:20 3918

Innovent Announces 2022 Annual Results and Business Updates

Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capabili...

2023-03-29 08:00 6102

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innove...

2023-03-21 08:00 5164

Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration

ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-02-28 08:00 5686

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innove...

2023-02-16 08:00 5009

Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-02-15 08:00 5452

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-01-18 21:34 4873

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-01-11 00:00 4546

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-01-10 00:00 4733

Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma

ROCKVILLE, Md. and SUZHOU, China, Jan. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-01-06 12:22 5151

Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-01-05 08:00 5629

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-01-05 00:00 3388

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-01-05 00:00 3475

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKE...

2022-12-15 08:00 5408

Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, Dec. 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-12-11 08:00 6338

Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

ROCKVILLE, Md. and SUZHOU, China, Dec 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-12-09 08:00 4571

Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

ROCKVILLE, Md. and SUZHOU, China, Dec. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-12-09 08:00 4747

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-12-05 08:00 4719

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-11-28 08:00 5780